| Cat.No. | Name | Information |
|---|---|---|
| M1959 | Oseltamivir | Oseltamivir is a potent and selective inhibitor of influenza virus neuraminidase enzyme. |
| M5055 | Peramivir | Peramivir is a transition-state analogue and a potent, specific influenza viral neuraminidase inhibitor with an IC50 of median 0.09 nM. |
| M1707 | Entecavir Monohydrate | Entecavir Hydrate is a class of antiviral compounds. |
| M3357 | Telbivudine | Telbivudine (Epavudine) is an orally active, potent antiviral inhibitor of hepatitis B virus (HBV) replication. Telbivudine is an antiviral compound used in hepatitis B research. |
| M1695 | Cidofovir | Cidofovir (Vistide) is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis. |
| M4718 | Dendrobine | Dendrobine is an alkaloid isolated from Dendrobium nobile. Dendrobine has antiviral activity against influenza A virus, IC50 values for A/FM-1/1/47 (H1N1), A/Puerto Rico/8/34 H274Y (H1N1) and A/Aichi/2/68 (H3N2) were 3.39 μM, 2.16 μM and 5.32 μM, respectively. |
| M3222 | Peramivir Trihydrate | Peramivir Trihydrate is a trihydrate of the anti-infection agent peramivir (RWJ-270201,BCX-1812) which is a transition-state analogue and a potent, specific influenza viral neuraminidase inhibitor with an IC50 of median 0.09 nM. |
| M4789 | Isoscopoletin | Isoscopoletin (6-Hydroxy-7-methoxycoumarin) is an active ingredient in artemisia argyi leaves. Isoscopoletin showed significant inhibition of cell proliferation, with IC50 values of 4.0 μM and 1.6 μM against human CCRF-CEM leukemia cells and CEM/ADR5000 drug-resistant subline, respectively. Isoscopoletin (6-Hydroxy-7-methoxycoumarin) has the activity of inhibiting HBV replication. |
| M10082 | Amodiaquine | Amodiaquine is a 4-aminoquinoline compound related to chloroquine, used as an antimalarial and anti-inflammatory agent. |
| M7775 | 3-Deazaadenosine | 3-Deazaadenosine is an inhibitor of S-adenosylhomocysteine hydrolase, with a Ki of 3.9 µM, possesses antiviral activity inhibitor of leukocyte adhesion to TNF-treated endothelial cells. |
| M25166 | Regdanvimab | Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19. |
| M25154 | Quisovalimab | Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies. |
| M25153 | Etesevimab | Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody. |
| M25152 | Bamlanivimab | Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and Drug Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab. |
| M25151 | Beludavimab | Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC50 value of 14.9 ng/mL and a Kd of 0.21 nM. |
| M25150 | Sotrovimab | Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease. |
| M25149 | Tixagevimab | Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor. |
| M25148 | Cilgavimab | Cilgavimab (AZD-1061; COV2-2130) is a humanized SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab . Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection. |
| M25146 | Mazorelvimab | Mazorelvimab (SYN023) is a combination of CTB011 and CTB012 humanized monoclonal antibodies cocktail against rabies virus (RABV). Mezagitamab binds to non-overlapping epitopes on RABV glycoprotein (G). Mezagitamab has potential application in the prevention of rabies. |
| M25135 | Alunacedase alfa | Alunacedase alfa (HrsACE2; GSK 2586881) is a human recombinant soluble angiotensin-converting enzyme-2 (hrsACE2). Alunacedase alfa is a genetically modified soluble form of ACE2, it decreases cell entry of SARS-CoV-2 competing for membrane-bound ACE2. Alunacedase alfa has the potential for the research of SARS-CoV-2. |
| M25132 | Casirivimab | Casirivimab (REGN10933) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Casirivimab lacks efficacy against COVID-19 variants. Casirivimab can be used in combination with Imdevimab , it reduces viral load and improves diseases. |
| M25131 | Imdevimab | Imdevimab (REGN10987) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Imdevimab lacks efficacy against COVID-19 variants. Imdevimab can be used in combination with Casirivimab , it reduces viral load and improves diseases. |
| M25076 | Enibarcimab | Enibarcimab is a humanised murine monoclonal immunoglobulin G1 (IgG1) antibody, could be used for acute heart failure, COVID-19 infections and septic shock research. |
| M25032 | Docaravimab | Docaravimab is an antibody, targeting ERA (Evelyn-Rockitniki-Abelseth) glycoprotein ectodomain epitope G-III. Docaravimab can be used in research of Rabies. |
| M25030 | Daxdilimab | Daxdilimab is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research. |
| M25021 | Omodenbamab | Omodenbamab is an anti-SpA (Staphylococcal protein A) humanized monoclonal antibody with a KD value of 0.0467 nM. Omodenbamab circumvents a key S. aureus evasion mechanism by targeting the cell wall moiety Protein A (SpA). Omodenbamab can be used in research of S. aureus bloodstream infection. |
| M24938 | Maftivimab | Maftivimab (REGN3470-3471-3479), the inhibitor of Filovirus, is an Food and Drug Administration (FDA)-approved agent. Maftivimab, also named as Atoltivimab, Odesivimab (Inmazeb), can be used for research of Zaire ebolavirus infection. |
| M24937 | Odesivimab | Odesivimab is a humanized monoclonal antibody, targeting Ebola virus glycoprotein with a KD value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein. Odesivimab can be used in research of Ebola virus infection. |
| M24936 | Atoltivimab | Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and Drug Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection. |
| M24890 | Lenvervimab | Lenvervimab (GC1102) is a IgG1-type recombinant human hepatitis B Immunoglobulin. Lenvervimab can be used for research of hepatitis B virus infection. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
